Literature DB >> 7568195

A mutant p53 antagonizes the deregulated c-myc-mediated enhancement of apoptosis and decrease in leukemogenicity.

J Lotem1, L Sachs.   

Abstract

Myeloid leukemic M1 cells that do not express p53 and transfected M1 clones that constitutively express the [Val135]p53 mutant or deregulated c-myc or coexpressing both genes grew autonomously in culture with a similar growth rate and cloning efficiency. Expression of deregulated c-myc in M1 leukemic cells enhanced susceptibility to induction of apoptotic cell death and resulted in a reduced leukemogenicity when injected into isologous mice. Expression of the [Val135]p53 mutant did not change cell susceptibility to induction of apoptosis or leukemogenicity, but expression of this mutant p53 suppressed the effects of deregulated c-myc on these properties. The results indicate that the [Val135]p53 mutant can show a gain of function for susceptibility to apoptosis and leukemogenicity in leukemic cells with deregulated c-myc and, thus, enhance tumor development.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7568195      PMCID: PMC40864          DOI: 10.1073/pnas.92.21.9672

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

Review 1.  Evolution of tumours and the impact of molecular oncology.

Authors:  G Klein; E Klein
Journal:  Nature       Date:  1985 May 16-22       Impact factor: 49.962

2.  Thymocyte apoptosis induced by p53-dependent and independent pathways.

Authors:  A R Clarke; C A Purdie; D J Harrison; R G Morris; C C Bird; M L Hooper; A H Wyllie
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

3.  p53 is required for radiation-induced apoptosis in mouse thymocytes.

Authors:  S W Lowe; E M Schmitt; S W Smith; B A Osborne; T Jacks
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

4.  Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents.

Authors:  J Lotem; L Sachs
Journal:  Blood       Date:  1993-08-15       Impact factor: 22.113

5.  Activation of apoptosis associated with enforced myc expression in myeloid progenitor cells is dominant to the suppression of apoptosis by interleukin-3 or erythropoietin.

Authors:  D S Askew; J N Ihle; J L Cleveland
Journal:  Blood       Date:  1993-10-01       Impact factor: 22.113

Review 6.  Control of programmed cell death in normal and leukemic cells: new implications for therapy.

Authors:  L Sachs; J Lotem
Journal:  Blood       Date:  1993-07-01       Impact factor: 22.113

7.  Gain of function mutations in p53.

Authors:  D Dittmer; S Pati; G Zambetti; S Chu; A K Teresky; M Moore; C Finlay; A J Levine
Journal:  Nat Genet       Date:  1993-05       Impact factor: 38.330

8.  Cooperative interaction between c-myc and bcl-2 proto-oncogenes.

Authors:  A Fanidi; E A Harrington; G I Evan
Journal:  Nature       Date:  1992-10-08       Impact factor: 49.962

9.  Coming to terms with death: apoptosis in cancer and immune development.

Authors:  J D Ashwell; N A Berger; J A Cidlowski; D P Lane; S J Korsmeyer
Journal:  Immunol Today       Date:  1994-04

10.  Complementation by wild-type p53 of interleukin-6 effects on M1 cells: induction of cell cycle exit and cooperativity with c-myc suppression.

Authors:  N Levy; E Yonish-Rouach; M Oren; A Kimchi
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

View more
  12 in total

1.  Apoptosis: A Current Molecular Analysis.

Authors:  Dean G Tang; Arthur T Porter
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

2.  Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis.

Authors:  D Matas; A Sigal; P Stambolsky; M Milyavsky; L Weisz; D Schwartz; N Goldfinger; V Rotter
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

3.  A role for c-myc in chemically induced renal-cell death.

Authors:  Y Zhan; J L Cleveland; J L Stevens
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

Review 4.  Mutant p53 gain-of-function in cancer.

Authors:  Moshe Oren; Varda Rotter
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02       Impact factor: 10.005

5.  Induction in myeloid leukemic cells of genes that are expressed in different normal tissues.

Authors:  Joseph Lotem; Hila Benjamin; Dvir Netanely; Eytan Domany; Leo Sachs
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-25       Impact factor: 11.205

6.  Cyclopentenyl cytosine induces senescence in breast cancer cells through the nucleolar stress response and activation of p53.

Authors:  Min Huang; Patrick Whang; Patrick Lewicki; Beverly S Mitchell
Journal:  Mol Pharmacol       Date:  2011-04-04       Impact factor: 4.436

Review 7.  The control of hematopoiesis and leukemia: from basic biology to the clinic.

Authors:  L Sachs
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

8.  The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.

Authors:  Giulia Fontemaggi; Stefania Dell'Orso; Daniela Trisciuoglio; Tal Shay; Elisa Melucci; Francesco Fazi; Irene Terrenato; Marcella Mottolese; Paola Muti; Eytan Domany; Donatella Del Bufalo; Sabrina Strano; Giovanni Blandino
Journal:  Nat Struct Mol Biol       Date:  2009-09-27       Impact factor: 15.369

9.  Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1.

Authors:  G Asher; J Lotem; B Cohen; L Sachs; Y Shaul
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-23       Impact factor: 11.205

10.  Mutant p53 mediates survival of breast cancer cells.

Authors:  L Y Lim; N Vidnovic; L W Ellisen; C-O Leong
Journal:  Br J Cancer       Date:  2009-09-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.